TD Asset Management’s LB Pharmaceuticals LBRX Stock Holding History

TD Asset Management’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-36,780	Closed	-$581K	–	1312
2025 Q3	$581K	Buy	+36,780	New	+$584K	﹤0.01%	1159

Other funds holding LBRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

TD Asset Management's LBRX Position: Q4 2025 in Review

TD Asset Management sold out of LB Pharmaceuticals (LBRX) in Q4 2025, closing a stake of 36,780 shares — an estimated $581K sold.

TD Asset Management first reported a position in LBRX in Q3 2025 and held it in 1 quarter. The position peaked at $581K in Q3 2025. 68 funds tracked by Wall St. Rank hold LBRX as of Q4 2025.

TD Asset Management reported no remaining LB Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
TD Asset Management sold 36,780 LB Pharmaceuticals shares in Q4 2025, an estimated $581K.
TD Asset Management first reported a position in LB Pharmaceuticals in Q3 2025 and held it in 1 quarter.
TD Asset Management's LB Pharmaceuticals position peaked at $581K in Q3 2025.
68 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q4 2025.

Based on TD Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.